Recurrent Prostate Cancer
... common way to treat prostate cancer. Surrounding tissues and nearby lymph nodes may also be removed. This procedure can be an option for some patients who previously had radiation therapy. Cryosurgery – One option for patients with localized cancer is cryosurgery, which uses super-cooled gas to free ...
... common way to treat prostate cancer. Surrounding tissues and nearby lymph nodes may also be removed. This procedure can be an option for some patients who previously had radiation therapy. Cryosurgery – One option for patients with localized cancer is cryosurgery, which uses super-cooled gas to free ...
View full press release - Prostate Cancer Canada
... Prostate Cancer Canada today announced $3 million in funding for a new Phase III clinical trial to evaluate if magnetic resonance imaging (MRI) can replace the current standard of care to diagnose prostate cancer. The primary objective of the multi-centre trial, called PRECISE, is to determine wheth ...
... Prostate Cancer Canada today announced $3 million in funding for a new Phase III clinical trial to evaluate if magnetic resonance imaging (MRI) can replace the current standard of care to diagnose prostate cancer. The primary objective of the multi-centre trial, called PRECISE, is to determine wheth ...
chicago symposium - The Prostate Net
... amounts to delayed treatment of cancer b) Repeated biopsies are: 1) Still subject to sampling errors 2) may induce inflammation that cause increased PSA levels 3) may cause scarring that makes nerve-sparing surgery difficult or impossible and may ...
... amounts to delayed treatment of cancer b) Repeated biopsies are: 1) Still subject to sampling errors 2) may induce inflammation that cause increased PSA levels 3) may cause scarring that makes nerve-sparing surgery difficult or impossible and may ...
MOD_GUAZZARONI_D`URSO_SIMONETTIi
... allows the evaluation of even smaller vessels than is currently possible [8, 10]. Preliminary studies have shown that the recently developed intravenous US contrast agents may have a possible role in the delineation of subtle prostate cancers with color Doppler flow imaging. Further research in this ...
... allows the evaluation of even smaller vessels than is currently possible [8, 10]. Preliminary studies have shown that the recently developed intravenous US contrast agents may have a possible role in the delineation of subtle prostate cancers with color Doppler flow imaging. Further research in this ...
Evaluation of Viable Dynamic Treatment Regimes in a Sequentially
... 1. Re-randomization design using “repeat a winner” and “switchaway from a loser” rules is a good idea. 2. Limitations of this study • Moderate sample size • Conservative simultaneous confidence intervals 3. Make sure you define patient outcome carefully. It is seldom binary or simple, and it sho ...
... 1. Re-randomization design using “repeat a winner” and “switchaway from a loser” rules is a good idea. 2. Limitations of this study • Moderate sample size • Conservative simultaneous confidence intervals 3. Make sure you define patient outcome carefully. It is seldom binary or simple, and it sho ...
Prostate Cancer Prevention - American Institute for Cancer Research
... Estimated fractions of total subjects with low-grade or high-grade PCA at PTX. ...
... Estimated fractions of total subjects with low-grade or high-grade PCA at PTX. ...
The Prostate-Specific Antigen (PSA) Test: Questions and Answers
... Why is the PSA test performed? The U.S. Food and Drug Administration (FDA) has approved the PSA test along with a digital rectal exam (DRE) to help detect prostate cancer in men age 50 and older. During a DRE, a doctor inserts a gloved finger into the rectum and feels the prostate gland through the ...
... Why is the PSA test performed? The U.S. Food and Drug Administration (FDA) has approved the PSA test along with a digital rectal exam (DRE) to help detect prostate cancer in men age 50 and older. During a DRE, a doctor inserts a gloved finger into the rectum and feels the prostate gland through the ...
INCREASED RISK OF PROSTATE CANCER IN
... evidence that high levels of Vitamin D are protective of prostate cancer (4, 5). There is agreement that environmental factors, including dietary influences, are important and a high intake of some vegetables including broccoli and tomatoes may be protective. ...
... evidence that high levels of Vitamin D are protective of prostate cancer (4, 5). There is agreement that environmental factors, including dietary influences, are important and a high intake of some vegetables including broccoli and tomatoes may be protective. ...
Prostate Cancer Screening - STA HealthCare Communications
... involved in the liquefaction of coagulated semen. It is found almost exclusively in the epithelial cells of the prostate and is easily measured in the blood. PSA increases proportionally with advanced PCa and is now used adjunctively with DRE for PCa detection. PCa screening is initiated in men at a ...
... involved in the liquefaction of coagulated semen. It is found almost exclusively in the epithelial cells of the prostate and is easily measured in the blood. PSA increases proportionally with advanced PCa and is now used adjunctively with DRE for PCa detection. PCa screening is initiated in men at a ...
PROSTATE CANCER The prostate is a walnut sized gland located
... There is currently no “best way” to detect prostate cancer in its early stages. Suspicion should be aroused by a strong family history of the cancer. The American Cancer Society currently recommends an annual digital rectal examination, a blood test- the PSA (prostatic specific antigen) for men olde ...
... There is currently no “best way” to detect prostate cancer in its early stages. Suspicion should be aroused by a strong family history of the cancer. The American Cancer Society currently recommends an annual digital rectal examination, a blood test- the PSA (prostatic specific antigen) for men olde ...
National Prostate Cancer Audit
... Senior clinicians and other members of the MDT should ensure that complete and accurate data can be submitted to the NPCA for every patient with newly diagnosed prostate cancer, including data on cancer stage and tumour grade ...
... Senior clinicians and other members of the MDT should ensure that complete and accurate data can be submitted to the NPCA for every patient with newly diagnosed prostate cancer, including data on cancer stage and tumour grade ...
PG12-34 Elliott Lay summary Principal Investigator: Professor David
... Androgen steroid hormones drive prostate cancer progression by turning genes on and off, leading to expression of new proteins which stimulate cell growth and division. We recently globally identified genes that are regulated in response to androgens. We have now correlated these with genes known to ...
... Androgen steroid hormones drive prostate cancer progression by turning genes on and off, leading to expression of new proteins which stimulate cell growth and division. We recently globally identified genes that are regulated in response to androgens. We have now correlated these with genes known to ...
prostate cancer - Cancer Research UK Publications
... I was diagnosed with prostate cancer in 2003 and initially had hormone therapy. When my PSA levels started to rise again, I took part in a series of clinical trials of different drugs including abiraterone. I also had a course of precision radiotherapy, which wasn’t even available 10 years ago. Than ...
... I was diagnosed with prostate cancer in 2003 and initially had hormone therapy. When my PSA levels started to rise again, I took part in a series of clinical trials of different drugs including abiraterone. I also had a course of precision radiotherapy, which wasn’t even available 10 years ago. Than ...
news release June 21, 2002 ASTRAZENECA RESPONDS TO FDA
... forward, including possibly requesting an advisory committee meeting. In addition, the FDA has suggested that we request a public hearing to review the data and discuss the findings in an open forum.” ‘Casodex’ 150mg is currently approved for the treatment of early or locally advanced prostate cance ...
... forward, including possibly requesting an advisory committee meeting. In addition, the FDA has suggested that we request a public hearing to review the data and discuss the findings in an open forum.” ‘Casodex’ 150mg is currently approved for the treatment of early or locally advanced prostate cance ...
Editorial Comment on: Post-treatment Prostate Biopsies in the Era of
... negative biopsy group. Astonishing, but not discussed, is the discrepancy of the 5-yr bDFS according to the ASTRO and Phoenix definition. The 5-yr bDFS for the Phoenix definition accounts for 87%, 65%, and 92% (p < 0.001) for the whole series, positive biopsy result, and negative biopsy result, resp ...
... negative biopsy group. Astonishing, but not discussed, is the discrepancy of the 5-yr bDFS according to the ASTRO and Phoenix definition. The 5-yr bDFS for the Phoenix definition accounts for 87%, 65%, and 92% (p < 0.001) for the whole series, positive biopsy result, and negative biopsy result, resp ...
